Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 2 1

Status

Active not recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 250Lymphoma 128Leukemia, Myeloid, Acute 103Lymphoma, Non-Hodgkin 98Precursor Cell Lymphoblastic Leukemia-Lymphoma 93Neoplasms, Plasma Cell 91Myelodysplastic Syndromes 91Leukemia 79Hodgkin Disease 78Lymphoma, Large B-Cell, Diffuse 66Leukemia, Lymphocytic, Chronic, B-Cell 65Lymphoma, Mantle-Cell 59Lymphoma, Follicular 57Neuroblastoma 44Burkitt Lymphoma 44Lymphoma, Large-Cell, Immunoblastic 40Lymphoma, B-Cell, Marginal Zone 37Recurrence 34Myeloproliferative Disorders 32Hematologic Neoplasms 32Leukemia, Myelogenous, Chronic, BCR-ABL Positive 30Immunoglobulin Light-chain Amyloidosis 29Leukemia, Myeloid, Accelerated Phase 25Leukemia, Myeloid, Chronic-Phase 24Congenital Abnormalities 24Leukemia, Myelomonocytic, Chronic 23Graft vs Host Disease 23Dendritic Cell Sarcoma, Interdigitating 21Waldenstrom Macroglobulinemia 20Melanoma 20

Interventions

Lenalidomide 17Dexamethasone 15Calcium Dobesilate 8daratumumab 5dexamethasone acetate 4dexamethasone 21-phosphate 4carfilzomib 4auricularum 4Melphalan 4Leflunomide 3Curcumin 3isatuximab 2iberdomide 2elotuzumab 2Peripheral Blood Stem Cell Transplantation 2PVX-410 vaccine 2Denosumab 2Cyclophosphamide 2Bortezomib 2siltuximab 1selinexor 1sargramostim 1pomalidomide 1poly ICLC 1piperine 1pembrolizumab 1ixazomib 1ibrutinib 1fludarabine phosphate 1fludarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Smoldering Multiple Myeloma × Melphalan × Clear all
NCT00114101 2026-04-29

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

National Cancer Institute (NCI)

Phase 3 Active not recruiting
460 enrolled 11 charts
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

NCT00112827 2025-06-06

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma

City of Hope Medical Center

Phase 1/2 Completed
54 enrolled 13 charts
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

NCT02415413 2022-09-10

Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma

PETHEMA Foundation

Phase 2 Active not recruiting
90 enrolled
Plasma cell

Smoldering Multiple Myeloma

NCT02353572 2015-03-09

Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

University of Colorado, Denver

Phase 1/2 Terminated
3 enrolled 5 charts
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡